Skip to main content

vidofludimus calcium anhydrous

Generic: Vidofludimus Calcium Anhydrous

vidofludimus calcium anhydrous: 2 clinical trials tracked.

vidofludimus calcium anhydrous evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about vidofludimus calcium anhydrous, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Multiple Sclerosis

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)

NCT05201638Registry updated 2026-10-01·Phase 3
Active, not recruiting

Primary endpoint: To evaluate efficacy of IMU-838 versus placebo based on time to first relapse

InterventionalRandomizedquadruple1,100 enrolledStarted 2022-01Completion 2033-10101 sites · Armenia, Bosnia and Herzegovina, Estonia, Germany…Immunic AG

A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)

NCT05134441Registry updated 2026-10-01·Phase 3
Active, not recruiting

Primary endpoint: To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse

InterventionalRandomizedquadruple1,121 enrolledStarted 2021-11Completion 2033-09103 sites · Albania, Algeria, Bulgaria, Georgia…Immunic AG